They will, however, formally include T. Rowe’s analyst stock ratings in their stock-selection model, which is a change from Nanda, who relied on analysts mainly for biotech picks. Adding forward ...

Like other portfolio managers at T. Rowe, he leverages the firm’s reputation and asset base to gain access to up-and-coming private companies, often in the fast-evolving biotech industry.

We spoke to an Oldham chippy that's closing after 25 years because of rising costs.